Lannett unveils FDA approved levothyroxine tablets in the US thyroid market
4 August 2020 -

Lannett Company Inc (NYSE:LCI) reported on Monday the availability of Cediprof Inc's US FDA approved levothyroxine Sodium Tablets USP under an interim exclusive supply and distribution agreement.

According to the companies, levothyroxine is a manufactured form of the thyroid hormone thyroxine. It is used to treat thyroid hormone deficiency, including the severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors.

Following two separate legal challenges by Cediprof's previous distributor of levothyroxine Sodium Tablets, the rulings now allows Lannett to commence distributing the procduct in the US.

Cediprof Inc is a part of the Neolpharma Pharmaceutical Group, which engages in the research, development, production and distribution of generic medicines in the following therapeutic areas: CNS, oncology, metabolic disease, rheumatology and infectious diseases.